Panelists discuss how immunoglobulin A (IgA) nephropathy’s progressive nature and significant economic impact demand a shift in payer perspective toward investing in disease-modifying therapies that, ...

Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing ...